logo-loader

Avalon GloboCare shares surge as recent momentum continues

Published: 14:41 05 Sep 2023 EDT

Avalon GloboCare Corp -

Avalon GloboCare Corp (NASDAQ:ALBT) shares climbed 29% to $1.24 on Tuesday after the precision diagnostics and clinical laboratory services provider said it received a new US patent titled "QTY Fc Fusion Water Soluble Receptor Proteins," a collaborative effort with Dr Shuguang Zhang of the Massachusetts Institute of Technology (MIT), which encompasses the composition and methodology for a groundbreaking technology known as the "QTY Code."  

According to the company, the QTY Code has the potential to transform water-insoluble transmembrane receptor proteins into their water-soluble counterparts, thereby expanding the horizon of therapeutic targets for conditions like cancer and diseases.  

On August 30, 2023, shares of Avalon GloboCare rose 10% after the company announced that its 40%-owned Laboratory Services MSO, LLC (LSM) is now offering an in-house laboratory developed test to detect tuberculosis using a patient’s sputum sample.   

LSM recently acquired Houston-based DE Laboratory LLC and opened a new laboratory in Scottsdale, Arizona. 

For fiscal 2022, LSM generated a profit of $6.3 million on $14.7 million in revenue. 

Avalon GloboCare noted that its profit-sharing arrangement with LSM is expected to result in "significant future cash flow" for Avalon. 

Contact Sean at sean@proactiveinvestors.com 

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 47 minutes ago